Belgian Metals and Mining Stock News

In recent weeks, the pan-European STOXX Europe 600 Index has experienced modest gains amid easing geopolitical tensions and robust corporate earnings, though market sentiment remains cautious due to potential U.S. tariff threats on EU goods. Against this backdrop of fluctuating market conditions, identifying promising small-cap stocks requires a keen eye for companies with strong fundamentals and growth potential that can navigate economic uncertainties effectively.

Shareholders might have noticed that Nyxoah SA ( EBR:NYXH ) filed its first-quarter result this time last week. The...

As you might know, KBC Group NV ( EBR:KBC ) recently reported its quarterly numbers. Revenues of €3.2b were in line...

Readers hoping to buy Melexis NV ( EBR:MELE ) for its dividend will need to make their move shortly, as the stock is...

Care Property Invest (ENXTBR:CPINV) has opened 2026 with Q1 revenue of €20.8m and net income of €17.9m, setting the tone for how investors will assess the latest numbers against a stock price of €12.90. The company has seen quarterly revenue move from €18.6m in Q1 2025 to €20.8m in Q1 2026. Trailing 12 month revenue sits at €77.4m alongside trailing net income of €59.0m, giving a clear picture of the recent income profile before factoring in dividends or valuation. With margins recently...

Dividend decision and leadership changes set the tone for NV Bekaert NV Bekaert (ENXTBR:BEKB) has just wrapped up an eventful May, with shareholders approving a gross dividend of €1.95 per share alongside director reappointments, while the company confirmed Q1 2026 sales in line with expectations. See our latest analysis for NV Bekaert. Following the annual meeting, Q1 sales update, recent acquisitions in Thailand and China, and the appointment of a new CEO, the stock’s 1-day share price...

KBC Group (ENXTBR:KBC) has opened 2026 with Q1 revenue of €3.1b and basic EPS of €1.32, setting the tone against a trailing twelve month backdrop of €12.1b in revenue and basic EPS of €8.67. Over recent quarters the company has seen revenue move from €2.6b in Q1 2025 to around €3.1b in Q1 2026, with basic EPS over that period ranging from about €1.28 to €2.50. This gives investors a clear view of how the top and bottom line are tracking into the new year. Taken together with a 28.6% net...

It looks like Kinepolis Group NV ( EBR:KIN ) is about to go ex-dividend in the next three days. The ex-dividend date is...

Proximus PLC has reported past first-quarter 2026 results showing sales of €1,510 million and revenue of €1,525 million, with net income of €124 million and basic earnings per share from continuing operations of €0.38, all lower than the same period a year earlier. This broad-based decline across sales, revenue and earnings measures raises questions about how effectively Proximus’s existing efficiency programs and investment plans are offsetting current pressures on its business. We’ll now...

Recent performance and context for Azelis Group Azelis Group (ENXTBR:AZE) has drawn investor attention after a mixed stretch for the stock, with a decline over the past week but gains over the past month and past 3 months. Over the past 7 days the stock fell 2.04%, while the month period shows a 13.34% gain and the past 3 months are up 8.62%. Year to date, the stock is up 13.28%, although the 1 year total return is down 27.88% and the 3 year total return is down 47.76%. See our latest...

It looks like KBC Group NV ( EBR:KBC ) is about to go ex-dividend in the next 4 days. The ex-dividend date is commonly...

Recent share performance and business context VGP (ENXTBR:VGP) has drawn investor attention after the stock declined 10.2% over the past day, extending falls of 5.6% over the past week and 11.3% over the past month. Those moves come as the €2.21b logistics and semi industrial real estate company, headquartered in Antwerp, continues to generate revenue of €191.99m and net income of €290.44m. This performance is partly supported by its renewable energy activities. See our latest analysis for...

Short term moves put Sofina Société Anonyme (ENXTBR:SOF) under the spotlight Sofina Société Anonyme (ENXTBR:SOF) has drawn attention after its stock fell 1.1% in the latest session and is now down about 2.3% over the past month and 12.5% over the past 3 months. With a market value of about €7.7b and a last close of €218.40, the company offers exposure to a broad mix of private equity and venture capital holdings spanning digital transformation, healthcare, education, consumer sectors and...

Viohalco (ENXTBR:VIO) drew attention after its stock climbed 13.55% in after-hours trading on EURONEXT on 7 May, as investors focused on its aluminium, copper, cables, and steel operations. See our latest analysis for Viohalco. That after hours jump adds to strong recent momentum, with a 7 day share price return of 16.45% and a 30 day share price return of 23.60%. The 1 year total shareholder return of 218.26% and 5 year total shareholder return of 288.09% underline how sentiment has shifted...

Syensqo SA/NV ( EBR:SYENS ) is about to trade ex-dividend in the next 2 days. Typically, the ex-dividend date is two...

NV Bekaert SA ( EBR:BEKB ) is about to trade ex-dividend in the next 3 days. The ex-dividend date generally occurs two...

Stock move puts Cmb.Tech (ENXTBR:CMBT) in focus Cmb.Tech (ENXTBR:CMBT) has drawn fresh attention after recent price action, with the stock last closing at €12.74. The company operates a business that spans marine transportation and hydrogen focused activities. See our latest analysis for Cmb.Tech. The recent 2.08% 1 day share price return and 15.19% 30 day share price return suggest positive momentum is building. The 57.77% 1 year total shareholder return and 166.44% 5 year total shareholder...

argenx (ENXTBR:ARGX) is back on investor radars after the FDA expanded the labels for Vyvgart and Vyvgart Hytrulo to cover all serotypes of adult generalized myasthenia gravis, significantly widening eligible patient coverage. See our latest analysis for argenx. The FDA label expansion lands after a busy stretch for argenx, including strong Q1 2026 results with higher Vyvgart sales, a CEO transition to Karen Massey, and a 1 year total shareholder return of 35.24%. However, the year to date...

Recent returns and what they might mean for investors KBC Ancora (ENXTBR:KBCA) has quietly posted mixed share price moves, with a 0.6% decline over the past day, a 2.2% gain over the past week, and around 4.5% over the past month. For longer term holders, the stock shows a modest gain of about 0.3% over the past 3 months, alongside a year to date return of roughly 5.4% and a 1 year total return close to 38.3%. See our latest analysis for KBC Ancora. With the share price at €79.4, KBC Ancora...

In April 2026, Melexis NV reported first quarter sales of €202.09 million, modestly above a year earlier, while net income eased to €23.09 million and basic EPS from continuing operations slipped to €0.57. At the same time, the company confirmed its 2026 guidance, expecting first half sales to be broadly unchanged year over year with an operating margin around 17% and indicating that second half sales should exceed the first half. We’ll now examine how Melexis’ confirmed first half operating...

Solvay stock moves after recent performance data Solvay (ENXTBR:SOLB) has come into focus after a period in which the stock showed negative returns over the past month and past 3 months, prompting closer attention to its fundamentals and profitability profile. See our latest analysis for Solvay. At a share price of €26.28, Solvay’s recent 7 day share price return of a 5.81% decline adds to a year to date share price return of a 3.88% decline, contrasting with a 42.41% three year total...

argenx (ENXTBR:ARGX) appointed Karen Massey as CEO, and co founder Tim Van Hauwermeiren moved to Chairperson. The company reported strong Q1 results, with accelerating VYVGART sales highlighted as a key driver. An FDA decision on a potential Vyvgart label expansion in seronegative generalized myasthenia gravis is expected soon. argenx focuses on antibody based therapies for autoimmune diseases, with VYVGART already a central product in its portfolio. For investors watching the immunology...

What the latest guidance and results mean for Melexis (ENXTBR:MELE) Melexis (ENXTBR:MELE) shares have been reacting to the company confirming its 2026 guidance alongside Q1 results, with sales at €202.09 million and net income at €23.09 million, compared with €24.6 million a year earlier. See our latest analysis for Melexis. The confirmation of 2026 guidance alongside Q1 results appears to have shifted sentiment, with the stock’s 30 day share price return of 39.34% and 1 year total...

Anheuser-Busch InBev (ENXTBR:ABI) has been named the 2026 Creative Marketer of the Year by the Cannes Lions International Festival of Creativity. This is the first time any company has received the award three times. The recognition follows the company winning 37 Lions at last year's festival. Anheuser-Busch InBev, the global brewer behind brands across beer and beyond, is being recognized for how it uses marketing and creativity across its portfolio. For investors, this award signals that...